You are here: Industry Insights > OncoSec

News List

OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO Combined with KEYTRUDA for Late-Stage Metastatic Melanoma firstwordpharma
July 07, 2021
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement with Merck to to evaluate the combination of OncoSec's DNA-plasmid interleukin-12
OncoSec Appoints Brian Leuthner as Interim CEO firstwordpharma
June 25, 2021
OncoSec Medical Incorporated (NASDAQ:ONCS) today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been appointed Interim Chief Executive Officer, effective June 25, 2021.
OncoSec Announces First Subjects Dosed in Phase 1 Trial of COVID-19 Vaccine americanpharmaceuticalreview
January 28, 2021
OncoSec Medical Incorporated has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19.
Sirtex Medical announces collaboration update with OncoSec Medical prnasia
January 20, 2021
Sirtex Medical US Holdings, Inc. announced an advancement in its strategic collaboration with OncoSec Medical, Inc. relating to OncoSec's lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
OncoSec Announces FDA Clearance for Trial of COVID-19 Vaccine Candidate americanpharmaceuticalreview
November 09, 2020
OncoSec Medical announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a first-in-human Phase 1 trial for CORVax12, a novel DNA-encodable vaccine against SARS-CoV-2 that the Company ...
OncoSec Announces Initiation of aStudy to Evaluate Melanoma Treatment americanpharmaceuticalreview
August 31, 2020
OncoSec Medical Incorporated announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D. of the H. Lee Moffitt Cancer Center and Research Institute and ...
OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership firstwordpharma
December 22, 2019
In the presentation, OncoSec also addresses the ongoing attempts by Alpha Holdings, Inc. ("Alpha") to prevent the special meeting to vote on the Transaction from ever happening by resorting to litigation and a potentially disenfranchising proxy scheme.
OncoSec Releases Interim Data from Ongoing Study of TAVO, KEYTRUDA® Combo americanpharmaceuticalreview
May 23, 2019
OncoSec Medical has announced interim data from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® in patients with heavily pretreated ...
OncoSec Granted Exclusive Worldwide Rights to Patent Portfolio for Use of IL-12 DNA americanpharmaceuticalreview
May 22, 2019
OncoSec announced the Company has been granted exclusive worldwide rights to Gaeta Therapeutics' portfolio of patents and applications covering the combination use of IL-12 DNA and ...
OncoSec, Gynecologic Oncology Group to Conduct Study of TAVO with KEYTRUDA americanpharmaceuticalreview
January 09, 2019
OncoSec has established a collaboration with the GOG Foundation to conduct a registration-enabled study of TAVO (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150)......

Previous page 1 2 Next page